Praluent, also known by its generic name alirocumab, is a medication used to lower LDL cholesterol levels [1]. It belongs to a class of drugs called PCSK9 inhibitors [2].
What is Praluent used for?
Praluent is prescribed for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol [1]. It is used along with diet and statin therapy, or alone if statins are not tolerated [1].
How does Praluent work?
Praluent works by inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein [2]. PCSK9 normally degrades LDL receptors in the liver, which are responsible for removing LDL cholesterol from the blood. By blocking PCSK9, Praluent allows more LDL receptors to be available on the liver surface, thereby increasing the clearance of LDL cholesterol from the bloodstream [2].
When does Praluent's patent expire?
Patent expirations for medications can be complex and involve multiple patents covering different aspects of the drug. Information on specific patent expiry dates for Praluent is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and their durations [3].
Can biosimilars of Praluent be developed?
The development of biosimilars for biologic medications like Praluent is possible after the expiry of relevant patents and regulatory exclusivities [4]. The timeline for biosimilar entry is contingent upon patent challenges and regulatory approvals [4].
What are the potential side effects of Praluent?
Common side effects associated with Praluent include nasopharyngitis (common cold), injection site reactions, and influenza [1]. More serious, though less common, side effects may include allergic reactions [1].
How is Praluent administered?
Praluent is administered as a subcutaneous injection, typically every two weeks or once a month, depending on the dosage [1]. Patients or their caregivers can be trained to administer the injections at home [1].
What are the alternatives to Praluent for lowering cholesterol?
Besides Praluent, other treatments for lowering LDL cholesterol include statins, ezetimibe, bile acid sequestrants, and other PCSK9 inhibitors like Repatha (evolocumab) [5]. Lifestyle modifications such as diet and exercise are also fundamental components of cholesterol management [5].